Thermo Fisher Scientific Inc. (TMO), a leading provider of scientific research services, has been witnessing various movements in its shareholding pattern. Entities such as B.O.S.S. Retirement Advisors, SG Americas Securities, Carr Financial, AEGON ASSET MANAGEMENT UK, and others have significantly sold their shares. Meanwhile, institutions like Grimes & Company, Brighton Jones, Fifth Third Bancorp, and others have grown their positions. Excitingly, the company's
Olink platform has been chosen for the largest human proteome study worldwide. Ahead of further earnings release, diverse views circulate among investment experts with some, like Jim Cramer, optimistic about the company's business rebounding by 2025. On another bright note, TMO's stock is tagged as a
low volatility investment, potentially offering safety to investors. In another significant move, the company has announced a
$4 billion share buyback program. Given all these activities, a
future bullish sentiment can be anticipated for Thermo Fisher Scientific Inc.
Thermo Fisher Scientific TMO News Analytics from Thu, 11 Jul 2024 07:00:00 GMT to Sat, 25 Jan 2025 14:37:01 GMT -
Rating 6
- Innovation 2
- Information 8
- Rumor -4
